June 4 (Reuters) - The UK cost-effectiveness watchdog on Thursday recommended AbbVie's "guided missile" cancer therapy, Elahere, for patients with a hard-to-treat form of ovarian cancer.
The drug, Elahere, will be made available to patients under a confidential commercial agreement between AbbVie and the state-run National Health Service, the National Institute for Health and Care Excellence (NICE) said.
The decision comes after NICE revised its value appraisal framework as part of a broader UK-U.S. deal last year to secure zero tariffs on British pharmaceutical products and medical technology, in exchange for increased drug spending and changes to its ******* sment criteria.
The new framework would widen access to treatments previously rejected on cost grounds.
Critically ill patients whose cancer has stopped responding to standard chemotherapy will now be able to access Elahere through the NHS. The drug was previously limited to clinical trials, private care, or compassionate use.
The drug, Elahere, will be made available to patients under a confidential commercial agreement between AbbVie and the state-run National Health Service, the National Institute for Health and Care Excellence (NICE) said.
The decision comes after NICE revised its value appraisal framework as part of a broader UK-U.S. deal last year to secure zero tariffs on British pharmaceutical products and medical technology, in exchange for increased drug spending and changes to its ******* sment criteria.
The new framework would widen access to treatments previously rejected on cost grounds.
Critically ill patients whose cancer has stopped responding to standard chemotherapy will now be able to access Elahere through the NHS. The drug was previously limited to clinical trials, private care, or compassionate use.
19 hours ago
